Drugs / Pascolizumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01638520 | Jun 2012 → Feb 2017 | pulmonary tuberculosis | National University Hospital, Singapore | Unknown | Mixed |
| Phase 2 | NCT00024544 | Aug 2001 → Feb 2003 | asthma | Facet Biotech | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pascolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00024544 ↗ |
| Known as | Anti-il-4 antibody | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108119 ↗ |
| Known as | ANTI-IL4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108119 ↗ |
| Known as | SB-240683 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108119 ↗ |
| Action | Inhibit | “We hypothesize that pascolizumab, an anti-IL-4 monoclonal antibody, might be of value as an adjunct to standard treatment.” NCT01638520 ↗1“Interleukin-4 inhibitor” CHEMBL2108119 ↗ |
| Modality | Monoclonal antibody | “We evaluated safety and efficacy of pascolizumab (humanized anti-IL-4 monoclonal antibody) as adjunctive tuberculosis treatment.” PMID 38527849 ↗ Sep 2024 |
| Route | Intravenous | “Participants with rifampicin-susceptible pulmonary tuberculosis received a single intravenous infusion of pascolizumab or placebo, and standard 6-month tuberculosis treatment.” PMID 38527849 ↗ Sep 2024 |
| Target | IL4 | “Interleukin-4 inhibitor” CHEMBL2108119 ↗ |